Drug Profile


Alternative Names: Adnectin™ BMS-844203; Angiocept; BMS-844203; CT-322

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Adnexus Therapeutics
  • Developer Adnexus Therapeutics; Bristol-Myers Squibb
  • Class Antineoplastics; Fibronectins
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Glioblastoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 23 Oct 2013 Discontinued - Phase-I for Glioblastoma (combination therapy, first-line therapy, newly diagnosed) in USA (IV)
  • 23 Oct 2013 Discontinued - Phase-II for Colorectal cancer (combination therapy, metastatic disease, second-line therapy or greater) in the USA, Argentina and Italy (IV)
  • 23 Oct 2013 Discontinued - Phase-II for Glioblastoma (combination therapy, recurrent, second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top